The Australia & New Zealand research antibodies market size is expected to reach USD 77.6 million by 2030, registering a CAGR of 4.8% from 2024 to 2030. Drivers of this market include rise in R&D initiatives being undertaken by biopharmaceutical & biotechnology companies, increase in government investments on R&D, and growth in neurobiology & stem cell research.
Rise in R&D investments and research activities by various pharmaceutical and biotechnology companies to develop new & innovative products is anticipated to fuel market growth. For instance, in March 2019, the Federal Government invested USD 150 million in Stem Cells Australia and University of Melbourne to support R&D pertaining to stem cell and explore new ways to treat various life-threatening conditions such as stroke, congenital heart disease, and kidney disease.
Growth in stem cell and neurobiology-based research is expected to boost the market during the forecast period. There are a number of neurobiology-based research institutes in Australia. For instance, the Center of Research Excellence in Neuromuscular Disorders, Australia, is a collaboration between neuromuscular experts.
Ongoing launch of new products is anticipated to fuel market growth over the forecast period. For instance, in April 2019, Bio-Rad launched a range of isotype-specific secondary antibodies-IgG1, IgG2a, and IgG2b. These products are used for specificity in ELISA, imaging, western blotting, and flow cytometry as well as to improve signaling.
Increasing adoption of strategies, such as collaborations and acquisitions, by leading market players is expected to fuel market growth. For instance, in March 2016, Thermo Fisher Scientific Inc., announced the acquisition of Affymetrix, Inc. This strategic acquisition was aimed at strengthening the company’s position in the field of bioscience and expanding its portfolio of antibodies.
New Zealand has been investing heavily in R&D in order to promote trade in biotechnology sector. According to Research, Science and Innovation System Performance Report, the nation’s total expenditure on R&D was estimated to be 1.23% of GDP in 2016. This was funded by both public and private firms in New Zealand. Data from the same source also indicates that the country’s science system is highly productive in terms of publications per researcher, with over USD 653,400 spent on research and higher education.
This product will be delivered within 2 business days.
Rise in R&D investments and research activities by various pharmaceutical and biotechnology companies to develop new & innovative products is anticipated to fuel market growth. For instance, in March 2019, the Federal Government invested USD 150 million in Stem Cells Australia and University of Melbourne to support R&D pertaining to stem cell and explore new ways to treat various life-threatening conditions such as stroke, congenital heart disease, and kidney disease.
Growth in stem cell and neurobiology-based research is expected to boost the market during the forecast period. There are a number of neurobiology-based research institutes in Australia. For instance, the Center of Research Excellence in Neuromuscular Disorders, Australia, is a collaboration between neuromuscular experts.
Ongoing launch of new products is anticipated to fuel market growth over the forecast period. For instance, in April 2019, Bio-Rad launched a range of isotype-specific secondary antibodies-IgG1, IgG2a, and IgG2b. These products are used for specificity in ELISA, imaging, western blotting, and flow cytometry as well as to improve signaling.
Increasing adoption of strategies, such as collaborations and acquisitions, by leading market players is expected to fuel market growth. For instance, in March 2016, Thermo Fisher Scientific Inc., announced the acquisition of Affymetrix, Inc. This strategic acquisition was aimed at strengthening the company’s position in the field of bioscience and expanding its portfolio of antibodies.
New Zealand has been investing heavily in R&D in order to promote trade in biotechnology sector. According to Research, Science and Innovation System Performance Report, the nation’s total expenditure on R&D was estimated to be 1.23% of GDP in 2016. This was funded by both public and private firms in New Zealand. Data from the same source also indicates that the country’s science system is highly productive in terms of publications per researcher, with over USD 653,400 spent on research and higher education.
Australia & New Zealand Research Antibodies Market Report Highlights
- Primary antibodies held dominant share of the product segment in 2023. This can be attributed to wide applications of these antibodies in research
- Monoclonal antibodies held significant share of the type segment in 2023, mainly due to their efficient staining properties and high specificity for detection of antigens
- Western blotting held the largest share of the technology segment owing to rising demand for rapid diagnostic methods
- On the basis of technology, ELISA is anticipated to witness the highest CAGR during the forecast period, owing to conventional use of polyclonal antibodies for sandwich ELISA
- On the basis of source, mouse segment held the largest share of the Australia & New Zealand research antibodies market in 2023, as mice are convenient to use during production of antibodies for research purposes
The leading players in the Australia & New Zealand Research Antibodies market include:
- Abcam Limited
- Bio-Rad Laboratories, Inc.
- BD
- Merck KGaA
- Lonza
- Thermo Fisher Scientific Inc.
- Cell Signaling Technology, Inc.
- F. Hoffmann-La Roche Ltd
- Agilent Technologies, Inc.
- Revvity
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Australia & New Zealand Research Antibodies Market Variables, Trends, & Scope
Chapter 4. Australia & New Zealand Research Antibodies Market: Product Estimates & Trend Analysis
Chapter 5. Australia & New Zealand Research Antibodies Market: Specificity Estimates & Trend Analysis
Chapter 6. Australia & New Zealand Research Antibodies Market: Technology Estimates & Trend Analysis
Chapter 7. Australia & New Zealand Research Antibodies Market: Source Estimates & Trend Analysis
Chapter 8. Australia & New Zealand Research Antibodies Market: Application Estimates & Trend Analysis
Chapter 9. Australia & New Zealand Research Antibodies Market: End-use Estimates & Trend Analysis
Chapter 10. Australia & New Zealand Research Antibodies Market: Country Estimates & Trend Analysis
Chapter 11. Competitive Landscape
Companies Mentioned
The leading players in the Australia & New Zealand Research Antibodies market include:- Abcam Limited
- Bio-Rad Laboratories, Inc.
- BD
- Merck KGaA
- Lonza
- Thermo Fisher Scientific Inc.
- Cell Signaling Technology, Inc.
- F. Hoffmann-La Roche Ltd
- Agilent Technologies, Inc.
- Revvity
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 70 |
| Published | September 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 55.7 Million |
| Forecasted Market Value ( USD | $ 77.6 Million |
| Compound Annual Growth Rate | 4.8% |
| Regions Covered | Australia, New Zealand |
| No. of Companies Mentioned | 11 |
